Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when MCRB files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsSeres Therapeutics schedules 2026 annual meeting for June 9, sets stockholder proposal deadline
Filed March 16, 2026 · Period ending March 16, 2026 · ~1 min read
Key Changes
-
low
Annual stockholder meeting scheduled for June 9, 2026, with April 13, 2026 record date for voting eligibility. This is a routine corporate governance event with no immediate business impact.
Item 8.01 verify on EDGAR → -
low
Stockholder proposals for inclusion in proxy materials must be received by March 26, 2026. The accelerated deadline reflects the meeting being held more than 30 days after last year's anniversary date.
Item 8.01 verify on EDGAR →
Summary
Seres Therapeutics filed a routine procedural 8-K announcing its 2026 annual stockholder meeting will be held on June 9, 2026. Stockholders of record as of April 13, 2026 will be eligible to vote on matters presented at the meeting.
The company also disclosed that stockholder proposals for inclusion in the proxy statement must be submitted by March 26, 2026, an accelerated deadline triggered by SEC rules when an annual meeting is scheduled more than 30 days after the prior year's meeting date. This filing has no material impact on the company's business operations, financial condition, or strategic direction.
It is purely administrative, fulfilling the company's disclosure obligations under securities regulations. Retail investors do not need to take any action unless they wish to submit a stockholder proposal, in which case they should note the March 26 deadline. Watch for the actual proxy statement in the coming weeks, which will detail the meeting agenda and any management or stockholder proposals up for vote.
Section-by-Section Diff
Event · Item 8.01 — Other Events
Seres Therapeutics schedules 2026 annual meeting for June 9, 2026 and sets March 26, 2026 deadline for stockholder proposals.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
In order for a stockholder proposal for the 2026 Annual Meeting to be eligible for inclusion in the Company’s proxy statement pursuant to Rule 14a-8 of the Exchange Act, the Company must receive the proposal and supporting statements at its principal executive office no later than the close of business on March 26, 2026 (which is the tenth (10th) day following the date of this Current Report on Form 8-K).
The deadline for stockholders to submit proposals for inclusion in the 2026 proxy statement is March 26, 2026. This revised deadline is necessary because the 2026 annual meeting is being held more than 30 days after the anniversary of the 2025 meeting, triggering special notice requirements under SEC rules.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 4, 2026 · How we verify